RxDoctor Payments Data

Yousef Hindi

Jackson, MSNPI 1972132751

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,521, 3.7 times the $411 reported in 2023.

$2,919in general payments, 2019–2025

Across 129 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$396
  • Pfizer$384
  • AstraZeneca$358
  • Boehringer Ingelheim$321
  • Merck$213
  • AbbVie$207
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$2,919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →